FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 260 filers reported holding FATE THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.86 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18 | -55.0% | 8,314 | 0.0% | 0.00% | – |
| Q2 2023 | $40 | -39.4% | 8,314 | -28.5% | 0.00% | -100.0% |
| Q1 2023 | $66 | -51.1% | 11,634 | -13.0% | 0.00% | 0.0% |
| Q4 2022 | $135 | -100.0% | 13,378 | 0.0% | 0.00% | -66.7% |
| Q3 2022 | $300,000 | -8.0% | 13,378 | +1.6% | 0.00% | 0.0% |
| Q2 2022 | $326,000 | -36.7% | 13,163 | -0.9% | 0.00% | -25.0% |
| Q1 2022 | $515,000 | -69.2% | 13,286 | -53.5% | 0.00% | -33.3% |
| Q4 2021 | $1,672,000 | +95.3% | 28,568 | +97.9% | 0.01% | -14.3% |
| Q3 2021 | $856,000 | -34.9% | 14,436 | -4.7% | 0.01% | -36.4% |
| Q2 2021 | $1,314,000 | +47.0% | 15,141 | +39.7% | 0.01% | -67.6% |
| Q1 2021 | $894,000 | -12.2% | 10,841 | -3.2% | 0.03% | -12.8% |
| Q4 2020 | $1,018,000 | +128.8% | 11,195 | +0.5% | 0.04% | +105.3% |
| Q3 2020 | $445,000 | +29.4% | 11,141 | +11.1% | 0.02% | +18.8% |
| Q2 2020 | $344,000 | +41.0% | 10,025 | -8.7% | 0.02% | +166.7% |
| Q1 2020 | $244,000 | +7.0% | 10,985 | -5.7% | 0.01% | +50.0% |
| Q4 2019 | $228,000 | – | 11,653 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $34,095 | 9.92% |
| Redmile Group, LLC | 12,957,222 | $130,738,370 | 5.35% |
| GCM Grosvenor Holdings, LLC | 1,037,256 | $10,465,913 | 2.67% |
| Casdin Capital, LLC | 2,050,000 | $20,684,500 | 1.60% |
| DAFNA Capital Management LLC | 550,940 | $5,558,985 | 1.57% |
| Artal Group S.A. | 2,600,000 | $26,234 | 1.46% |
| Monaco Asset Management SAM | 250,000 | $2,522,500 | 0.76% |
| Parametrica Management Ltd | 32,254 | $325,443 | 0.67% |
| Boxer Capital, LLC | 1,250,000 | $12,612,500 | 0.66% |
| Bellevue Group AG | 4,861,279 | $49,050,305 | 0.65% |